血管內(nèi)皮細(xì)胞蛋白C受體(EPCR)活性蛋白
Active Endothelial protein C receptor (EPCR)
CD201; PROCR; CCCA ;CCD41; BA42O4.2; EPCR; Endothelial Protein C Receptor; Cell Cycle, Centrosome-Associated Protein; Activated Protein C Receptor
- 編號(hào)APA022Hu02
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 80%
- 等電點(diǎn)6.7
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載 英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 1176 ¥ 2940 ¥ 5880 ¥ 17640 ¥ 44100
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
活性實(shí)驗(yàn)
Endothelial protein C receptor (EPCR) also known as CD201, is a transmembrane glycoprotein expressed on vascular endothelial cells and functions as a negative regulator of thrombosis. It is expressed most strongly in the endothelial cells of arteries and veins in heart and lung. Mature human EPCR consists of a 193?amino acid (aa) extracellular domain (ECD), a 21?aa transmembrane segment, and a 7?aa cytoplasmic tail. Within the ECD, human EPCR shares 63%?and 66%?aa sequence identity with mouse and rat EPCR, respectively. EPCR inhibits thrombosis through its interactions with Protein?C, activated Protein C (APC), and Coagulation Factors VII, and VIIa. Thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human EPCR and recombinant rat Coagulation Factor VII (F7). Briefly, EPCR was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to F7-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-EPCR pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 μL stop solution to the wells and read at 450/630nm immediately. The binding activity of recombinant human EPCR and recombinant rat F7 was shown in Figure 1, the EC50?for this effect is 0.06 ug/mL.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過(guò)一個(gè)月,-80°C不超過(guò)12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲(chǔ),損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
APA022Hu02 | 血管內(nèi)皮細(xì)胞蛋白C受體(EPCR)活性蛋白 | Cell?culture;?Activity?Assays. |
RPA022Hu01 | 血管內(nèi)皮細(xì)胞蛋白C受體(EPCR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA022Hu01 | 血管內(nèi)皮細(xì)胞蛋白C受體(EPCR)多克隆抗體 | WB; IHC; ICC; IP. |
LAA022Hu71 | 血管內(nèi)皮細(xì)胞蛋白C受體(EPCR)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
MAA022Hu22 | 血管內(nèi)皮細(xì)胞蛋白C受體(EPCR)單克隆抗體 | WB; IHC; ICC; IP. |
SEA022Hu | 血管內(nèi)皮細(xì)胞蛋白C受體(EPCR)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA022Hu | 血管內(nèi)皮細(xì)胞蛋白C受體(EPCR)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
ВЕСТНИК НОВЫХ МЕДИЦИНСКИХ ТЕХНОЛОГИЙ | СОВЕРШЕНСТВОВАНИЕ ЛЕЧЕБНО-ДИАГНОСТИЧЕСКИХ МЕРОПРИЯТИЙ ПРИ ГРИППЕ ВО ВРЕМЯ БЕРЕМЕННОСТИ [Bulletin: E2015-1] |
Experimental and Therapeutic Medicine | Unfractionated heparin protects the protein C system against lipopolysaccharide?induced damage in vivo and in vitro [10.3892/etm.2017.5236] |
Biomed Pharmacother | Effects and mechanisms of PSS-loaded nanoparticles on coronary microcirculation dysfunction in streptozotocin-induced diabetic cardiomyopathy rats [Pubmed: 31715373] |
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE | Effect of Nitinol on Metabolic and Coagulation Activity of Endothelial Cells Culture [34542754] |